Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Description

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.

Conditions

Non Small Cell Lung Cancer, Glioma Glioblastoma Multiforme, Glioma, Malignant, Solid Tumor, Non-Small Cell Adenocarcinoma, Lung Cancer, Brain Tumor

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tumor types with a confirmed MTAP loss. The study drug, TNG456, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 191 participants.

A Phase 1/2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Antitumor Activity of TNG456 Monotherapy and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Condition
Non Small Cell Lung Cancer
Intervention / Treatment

-

Contacts and Locations

Fairfax

NEXT Virginia, Fairfax, Virginia, United States, 22031

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Has a tumor with a confirmed MTAP loss
  • * Is ≥18 years of age at the time of signature of the main study ICF
  • * Has had progression or an inadequate response to or is intolerant of the approved standard of care therapy, no standard of care therapy exists, or the investigator has determined that treatment with the standard of care therapy is not appropriate.
  • * Is able to swallow tablets
  • * Adequate Organ function/reserve per local labs
  • * Negative serum pregnancy test result at screening
  • * Has an ECOG performance status score of 0 to 1
  • * Has measurable disease based on RECIST v1.1 or a confirmed glioblastoma (IDH-wildtype) with radiographic evidence of disease progression or recurrence defined by RANO 2.0.
  • * Has an ECOG performance score of 0 to 1 or for GBM has a Karnofsky performance status score ≥70.
  • * A female patient is who is pregnant or breastfeeding
  • * Has impaired GI function or disease that may significantly alter the absorption of oral study treatment(s)
  • * Has an active infection requiring systemic therapy
  • * Has received prior treatment with a PRMT5 inhibitor or a MAT2A inhibitor
  • * Patients in the expansion receiving the combination therapy that have received prior treatment with a CDK4/6 inhibitor
  • * Clinically relevant cardiovascular disease
  • * Has a prior or ongoing clinically significant illness may affect the safety of the patient, impair the assessment of study results or compliance with the protocol

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

Tango Therapeutics, Inc.,

Maeve Waldron-Lynch, MD, STUDY_DIRECTOR, Tango Therapeutics, Inc.

Study Record Dates

2027-09-30